Liquid biopsy startup Senticell closed an oversubscribed seed round approaching $7 million to advance an RBC-bound nucleic acid platform licensed exclusively from the University of Pennsylvania. The company says its red-blood-cell-based assay can capture disease signals it believes plasma tests miss, and it is running two oncology studies at Penn Medicine enrolling about 300 patients.